Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

Phase I Study of ONCOS-102 in late-stage refractory cancer patients successfully completed and showing excellent safety profile.
Read More